Processing
The xGen Acute Myeloid Leukemia Cancer Panel is a target enrichment solution for next generation sequencing (NGS) composed of more than 11,500 xGen Lockdown Probes targeting 260 genes implicated in acute myeloid leukemia (AML). This 1.2 Mb panel was developed as part of The Cancer Genome Atlas (TCGA) project collaboration [1]. The capture probes are biotin-modified oligonucleotides individually synthesized using proprietary IDT Ultramer® synthesis technology, ensuring probes of the highest quality and industry-leading yields of full-length product. The AML Cancer Panel also offers an unprecedented level of flexibility, including allowing for expansion to cover more targets, and can also be used as a supplement for exome enrichment.
The xGen AML Cancer Panel is empirically derived from 200 patient samples and achieves coverage of >99.9% of target regions with highly uniform enrichment (Figure 1). The panel is compatible with the optimized xGen 4-hour Capture Protocol, which allows sequencing to be started on the same day that target capture is performed. This stocked, functionally validated product is shipped in 1 business day after an order is received.
Figure 1. Highly uniform enrichment from xGen AML Cancer Panel. A 4-plex target capture of human genomic DNA (Coriell) performed using the xGen AML Cancer Panel using TruSeq® LT libraries was sequenced on an Illumina MiSeq using 2 x 150 paired-end reads. A cumulative 31.8M reads were generated for all 4 samples. Greater than 98% of targets are covered at >0.2 of the mean coverage. Mean coverage depth ranged from 218X to 510X as a result of expected sample-to-sample variability.
To order the xGen AML Cancer Panel or learn more about its features, click here.
